Salvage Chemotherapy After Pembrolizumab for Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma
In Vivo · 2026-11 · 40 (6) · 3648-3656
DOI: 10.21873/invivo.14503 ↗Kurz gefasst
Multizentrische Studie in der Zeitschrift In Vivo, online erschienen am 29.10.2026. Verfasst von Chihiro Fushimi und 17 weiteren Autor:innen. Beteiligte Einrichtung: Department of Head and Neck Oncology and Surgery, International University of Health and Welfare Mita Hospital, Tokyo, Japan; chfushim@ncc.go.jp. Hauptthemen laut MEDLINE: Antibodies, Monoclonal, Humanized, Salvage Therapy, Squamous Cell Carcinoma of Head and Neck, Neoplasm Recurrence, Local. Der Volltext ist frei in PubMed Central verfügbar.
Themen: Onkologische Pflege
Abstract (Originalsprache)
Kein Abstract verfügbar.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Head and Neck Oncology and Surgery, International University of Health and Welfare Mita Hospital, Tokyo, Japan; chfushim@ncc.go.jp.
- Department of Head and Neck Surgery, National Cancer Center Hospital, Tokyo, Japan.
- Department of Otorhinolaryngology, Head and Neck Surgery, Tokyo Medical University, Tokyo, Japan.
- Department of Otorhinolaryngology, Head and Neck Surgery, Kitasato University School of Medicine, Kanagawa, Japan.
- Department of Head and Neck Surgery, Kanagawa Cancer Center, Kanagawa, Japan.
- Department of Otorhinolaryngology, Head and Neck Surgery, Yokohama City University, Kanagawa, Japan.
Zitieren
APA
Fushimi, C., Okamoto, I., Matsuki, T., Okada, T., Ueda, Y., Takahashi, H., Sato, H., Kondo, T., Tokashiki, K., Hanyu, K., Ito, T., Kushihashi, Y., Masubuchi, T., Tada, Y., Omura, G. O., Yamashita, T., Oridate, N., & Tsukahara, K. (2026). Salvage Chemotherapy After Pembrolizumab for Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma. In Vivo, 40(6), 3648-3656. https://doi.org/10.21873/invivo.14503
Vancouver
Fushimi C, Okamoto I, Matsuki T, Okada T, Ueda Y, Takahashi H, et al. Salvage Chemotherapy After Pembrolizumab for Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma. In Vivo. 2026;40(6):3648-3656. doi:10.21873/invivo.14503
BibTeX
@article{Fushimi2026,
author = {Fushimi, Chihiro and Okamoto, Isaku and Matsuki, Takashi and Okada, Takuro and Ueda, Yuri and Takahashi, Hideaki and Sato, Hiroki and Kondo, Takahito and Tokashiki, Kunihiko and Hanyu, Kenji and Ito, Tatsuya and Kushihashi, Yukiomi and Masubuchi, Tatsuo and Tada, Yuichiro and Omura, G O and Yamashita, Taku and Oridate, Nobuhiko and Tsukahara, Kiyoaki},
title = {Salvage Chemotherapy After Pembrolizumab for Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma},
journal = {In Vivo},
year = {2026},
volume = {40},
number = {6},
pages = {3648--3656},
doi = {10.21873/invivo.14503}
}
EUVIMED